1
|
Attari H, Cao Y, Elmholdt TR, Zhao Y, Prince MR. A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis. Radiology 2019; 292:376-386. [PMID: 31264946 DOI: 10.1148/radiol.2019182916] [Citation(s) in RCA: 70] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Background Although nephrogenic systemic fibrosis (NSF) affects the use of gadolinium-based contrast agents (GBCAs) in MRI, there continues to be limited knowledge because of the small number of patients with NSF. Purpose To perform a systematic review of NSF. Materials and Methods PubMed database was searched by using the term "Nephrogenic systemic fibrosis" from January 2000 to February 2019. Articles reporting details on individual patients with NSF diagnosis on the basis of both clinical presentations and biopsy confirmation were included. Data were pooled and authors were contacted for clarifications. Rates of NSF were compared through 2008 versus after 2008 and for group I versus group II GBCAs, assuming equal market share. Results Included were 639 patients from 173 articles. Data regarding sex were found for 295 men and 254 women. Age at NSF symptom onset was reported for 177 patients (mean, 49 years ± 16 [standard deviation]; age range, 6-87 years). There were 529 patients with documented exposure to GBCAs including gadodiamide (n = 307), gadopentetate dimeglumine (n = 49), gadoversetamide (n = 6), gadobutrol (n = 1), gadobenate dimeglumine (n = 1), multiple (n = 41), and unknown (n = 120). Among patients with previous exposure, only seven patients were administered GBCA after 2008, yielding a lower rate of NSF after 2008 (P < .001). There were motion limitations in 70.8% (296 of 418) of patients, indicating a more serious debilitation. Associated factors reported for NSF included exposure to GBCA group I (P < .001), dialysis, proinflammatory conditions, hyperphosphatemia, β-blockers, and epoetin. For 341 patients with follow-up, 12 patients were cured and 72 patients partially improved including one during pregnancy. Among those 84 patients reported as cured or improved, in 34 patients cure or improvement occurred after renal function restoration. Four deaths were attributed to NSF. Conclusion Although 639 patients with biopsy-confirmed nephrogenic systemic fibrosis were reported, only seven were after gadolinium-based contrast agent exposure after 2008, indicating that regulatory actions and practice changes have been effective preventive measures. Improvement and sometimes cure with renal function restoration are now possible. © RSNA, 2019 See also the editorial by Davenport in this issue.
Collapse
Affiliation(s)
- Hanieh Attari
- From the Department of Radiology, Weill Cornell Medical College & New York Presbyterian Hospital, 416 E 55th St, New York, NY 10022 (H.A., Y.Z., M.R.P.); Department of Radiology, Wayne State University/Detroit Medical Center, Detroit, Mich (Y.C.); Department of Children and Adolescent Psychiatry, Aarhus University Hospital, Aarhus, Denmark (T.R.E.); and Department of Radiology, Columbia University College of Physicians and Surgeons, New York, NY (M.R.P.)
| | - Yan Cao
- From the Department of Radiology, Weill Cornell Medical College & New York Presbyterian Hospital, 416 E 55th St, New York, NY 10022 (H.A., Y.Z., M.R.P.); Department of Radiology, Wayne State University/Detroit Medical Center, Detroit, Mich (Y.C.); Department of Children and Adolescent Psychiatry, Aarhus University Hospital, Aarhus, Denmark (T.R.E.); and Department of Radiology, Columbia University College of Physicians and Surgeons, New York, NY (M.R.P.)
| | - Tina R Elmholdt
- From the Department of Radiology, Weill Cornell Medical College & New York Presbyterian Hospital, 416 E 55th St, New York, NY 10022 (H.A., Y.Z., M.R.P.); Department of Radiology, Wayne State University/Detroit Medical Center, Detroit, Mich (Y.C.); Department of Children and Adolescent Psychiatry, Aarhus University Hospital, Aarhus, Denmark (T.R.E.); and Department of Radiology, Columbia University College of Physicians and Surgeons, New York, NY (M.R.P.)
| | - Yize Zhao
- From the Department of Radiology, Weill Cornell Medical College & New York Presbyterian Hospital, 416 E 55th St, New York, NY 10022 (H.A., Y.Z., M.R.P.); Department of Radiology, Wayne State University/Detroit Medical Center, Detroit, Mich (Y.C.); Department of Children and Adolescent Psychiatry, Aarhus University Hospital, Aarhus, Denmark (T.R.E.); and Department of Radiology, Columbia University College of Physicians and Surgeons, New York, NY (M.R.P.)
| | - Martin R Prince
- From the Department of Radiology, Weill Cornell Medical College & New York Presbyterian Hospital, 416 E 55th St, New York, NY 10022 (H.A., Y.Z., M.R.P.); Department of Radiology, Wayne State University/Detroit Medical Center, Detroit, Mich (Y.C.); Department of Children and Adolescent Psychiatry, Aarhus University Hospital, Aarhus, Denmark (T.R.E.); and Department of Radiology, Columbia University College of Physicians and Surgeons, New York, NY (M.R.P.)
| |
Collapse
|
2
|
Abstract
Clinicians, radiologists, and patients should be aware of the most up-to-date data on the risks of gadolinium-based contrast agent (GBCA) administration. In this review, we discuss in vivo gadolinium retention, particularly brain tissue retention, and potential toxic effects. GBCA pharmacokinetics and biodistribution are reviewed briefly. Based on the more recent published literature and society guidelines, general safety recommendations for clinical practice are provided.
Collapse
Affiliation(s)
- Joana Ramalho
- Department of Neuroradiology, Centro Hospitalar de Lisboa Central, Rua José António Serrano, 1150-199 Lisboa, Portugal.
| | - Miguel Ramalho
- Department of Radiology, Hospital Garcia de Orta, Avenida Torrado da Silva, 2805-267 Almada, Portugal
| |
Collapse
|